UK Cardiovascular Diseases Therapeutics Market Analysis

UK Cardiovascular Disease Therapeutics Market Executive Analysis

UK's cardiovascular disease therapeutics market is projected to grow from $4.22 Bn in 2022 to $6.35 Bn in 2030 with a CAGR of 5.22% for the year 2022-30. The Chancellor pledged an additional $3.53 Bn for the National Health Service (NHS) in the 2022 Autumn Statement, as well as £1.4 Bn for capital expenditures in 2023-24 and 2024-25. Spending in 2024-25 will be nearly $15 Bn more than in 2022-23 in terms of money. As a result, core annual day-to-day NHS spending will increase by 2% by 2024-25 while capital spending will only expand by 0.2%. Over the next two years, the budget settlement for the Department of Health and Social Care will rise overall by 1.2% a year in real terms. This is more than what was anticipated in the previous spending review, but it is still much lower than the long-term average increase rate of 3.6%.

Despite decades of advancements in research, better treatments, and initiatives to raise public awareness of lifestyle risk factors that can contribute to the development of some cardiovascular diseases (CVD), CVD continues to be the top cause of mortality in the UK. Morbidity-wise, CVD continues to be a major burden in the UK, causing at least 1.18 Mn hospital admissions and reflecting the CVD's enormous economic burden, which is assessed to be $20 Bn in the country.

Inclisiran, a cholesterol-lowering medication that has not yet received FDA approval, will be tested on patients in the UK as part of a significant NHS clinical study that is anticipated to begin later this year. Additionally, in a first for the world, the drug is anticipated to be made accessible via a population-level agreement, ushering in a revolutionary method of lowering the risk of heart disease. Over three Mn people have atherosclerotic cardiovascular disease, and 2.5 Mn of them presently take statins to reduce their cholesterol. Heart disease is the second leading cause of death in the UK and the leading cause of death globally. In just two weeks, inclisiran can reduce bad LDL by half, according to recent studies. This emphasizes the UK is a top location to deliver novel medications to patients more quickly and affordably. Similar agreements could be made for other large-scale drug development initiatives thanks to its appetite for innovation, unmatched infrastructure, and the world-class integrated healthcare system.

Market Dynamics

Market Growth Drivers

The majority of deaths in the UK are caused by cardiovascular diseases (CVD), which account for nearly one-third of all fatalities. Due to factors like an aging population and an increase in risk factors like obesity, diabetes, and high blood pressure, it is anticipated that the frequency of CVD will rise in the upcoming years. The cardiovascular disease therapeutics market is anticipated to increase as a result. Pharmaceutical firms are making significant investments in the study and development of novel treatments for cardiovascular disease. As a result, both novel drugs are currently being developed and existing drugs are being improved. For instance, the creation of PCSK9 inhibitors, a new kind of cholesterol-lowering drug, can completely alter the way cardiovascular disease is treated.

Market Restraints

It is expensive and time-consuming to develop novel treatments for cardiovascular disease. A lack of funding for drug development on the part of smaller pharmaceutical firms may reduce the number of drugs that are available on the market. High drug prices may restrict patients' access to some treatments as a result of high drug development expenses. Existing therapies for cardiovascular illness see the availability of generic versions as their patents expire. Price competition and decreased revenue for the pharmaceutical companies that produced the initial drugs can result from this thereby limiting the expansion of the UK cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

• Kliklok International (GBR)
• Bioventus Pharmaceuticals (GBR)
• Pharma Medico (GBR)
• Ackerley Pharma (GBR)
• eXmoor Pharma (GBR)
• Bristol-Myers Squibb
• Pfizer
• Bayer
• Janssen Pharmaceuticals
• AstraZeneca
• Sanofi
• Novartis

Healthcare Policies and Regulatory Landscape

The National Health Service (NHS), which is publicly financed and offers healthcare free of charge to UK citizens, is in charge of providing healthcare in the country. The diagnosis and treatment of cardiovascular disease (CVD) are among the medical treatments covered by the NHS. The National Institute for Health and Care Excellence (NICE) has established a set of rules that the NHS must abide by when it comes to paying for CVD therapies. NICE offers recommendations for the best and most affordable treatments for a range of medical problems, including CVD. The NHS uses these standards to determine which treatments to fund and reimburse. For example, NICE advises that patients who have a high chance of developing CVD be offered statins, which are medications used to lower cholesterol levels. Therefore, for those who qualify, the NHS will pay for the expense of statins. The NHS also provides a variety of surgical and non-surgical treatments for CVD, such as coronary artery bypass surgery and angioplasty, in addition to drug therapies. In the UK, private health insurance is also an option, and some policies might pay for CVD treatments not covered by the NHS. Private health insurance, on the other hand, is frequently more costly than using the NHS and might not be available to all patients.